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Abstract
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Objective—Low-density lipoprotein cholesterol (LDL-C) is a risk factor for survival in middleaged individuals, but conflicting evidence exists on the relationship between LDL-C and all-cause
mortality among the elderly. The goal of this study was to assess the relationship between LDL-C
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and all-cause mortality among Chinese oldest old (aged 80 and older) in a prospective cohort
study.
Methods—LDL-C concentration was measured at baseline and all-cause mortality was
calculated over a 3-year period. Multiple statistical models were used to adjust for demographic
and biological covariates.
Results—During three years of follow-up, 447 of 935 participants died, and the overall all-cause
mortality was 49.8%. Each 1 mmol/L increase of LDL-C concentration corresponded to a 19%
decrease in 3-year all-cause mortality (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.71–
0.92). The crude HR for abnormally higher LDL-C concentration (≥3.37 mmol/L) was 0.65 (0.41–
1.03); and the adjusted HR was statistically significant around 0.60 (0.37–0.95) when adjusted for
different sets of confounding factors. Results of sensitivity analysis also showed a significant
association between higher LDL-C and lower mortality risk.
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Conclusions—Among the Chinese oldest old, higher LDL-C level was associated with lower
risk of all-cause mortality. Our findings suggested the necessity of re-evaluating the optimal level
of LDL-C among the oldest old.
Keywords
LDL-C; mortality; oldest old; epidemiology; China

Introduction
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Low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular and
cerebrovascular diseases and is associated with increased mortality in middle-aged
individuals [1]. For the elderly, however, there are three concerns that cast doubt on the
applicability of general LDL-C recommendations. First, studies of older populations have
led to conflicting conclusions on the relationship between LDL-C and all-cause mortality.
Some studies showed that high concentrations of LDL-C were associated with higher risk of
mortality and morbidity of cardiovascular and cerebrovascular diseases or all-cause
mortality among the elderly [2, 3], while other studies found that low LDL-C concentrations
were associated with increased mortality risk from non-cardiovascular disease [4], such as
cancer [5], infection [6], liver diseases [7], and trauma [8] among elderly. Several studies
also concluded that LDL-C was inversely associated with the risk of death in elderly people
[9–14], which has attracted particular attention regarding the necessity for LDL-C lowering
therapy in the aged population.
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A second concern about the generalizability of lipid treatment recommendations is that most
studies have been conducted in high-income countries. Understanding this relationship in
low-income and heavily populated countries is particularly urgent as they confronting the
challenge of a rapidly increasing aging population.
A third concern is that currently almost all the recommendations to lower the level of LDLC were formulated for the general adult population [15–17], and there were very few studies
that focused on the optimal LDL-C level of the oldest old. To investigate this question, we
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assessed the relationship between LDL-C and all-cause mortality in a longitudinal cohort of
oldest old in China.

Methods
Study Design and Participants

Author Manuscript

We used data collected in the Chinese Longitudinal Healthy Longevity Survey (CLHLS).
The study design of CLHLS has been described in detail elsewhere [18]. The baseline
survey of this current study was conducted in 2009, in 7 longevity areas of China, and 935
aged 80 years or older participated in the baseline survey, including 319 octogenarians, 276
nonagenarians and 340 centenarians. The follow-up survey was conducted in 2012. The
study was approved by the Ethics Committee of Peking University and the Ethics
Committee of the National University of Singapore. Written consent was obtained from all
participants.
Participants were followed-up for a length of 38 months from the baseline survey in June
2009 to August 2012. Participants’ survival status was ascertained during the follow-up
survey. Dates of death were acquired and confirmed by participants’ family members or the
village doctor. The information on cause-specific death was not collected in this study
because (1) the seven survey fields are not covered by the death surveillance system in
China, (2) reported conditions prior to death do not provide clear insight into the cause of
death in the oldest old with a variety of chronic diseases, and (3) many of the oldest old die a
natural death at home rather than in hospital where cause of death may be assessed. A ‘lostto-follow-up’ status was assigned to those who could not be found and contacted.
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Data Collection
Baseline assessments included a researcher-administered questionnaire, physical
examination, and laboratory testing. All the questions were answered by the participants
themselves or with their family members if the participants were unable to complete
interviews. The following information was collected: socioeconomic and demographic
characteristics, dietary behaviors and life style, diseases, cognitive function, and the
performance of activities of daily living (ADL).
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Physical examination was performed to measure systolic blood pressure (SBP), diastolic
blood pressure (DBP), waist circumference (WC), and vision. Five milliliters of venous
blood and 15 milliliters of urine were collected in the morning after an overnight fast for at
least 12 hours. Serum creatinine was determined with the picric acid method and
albuminuria was measured by dry chemistry reagent test strips (Siemens Diagnostics, NY,
USA). Fasting plasma glucose, hemoglobin, LDL-C and high-density lipoprotein cholesterol
(HDL-C) were measured by an Automatic Biochemistry Analyzer (Hitachi 7180, Japan)
using commercially available diagnostic kits (Roche Diagnostic, Mannheim, Germany) at
Capital Medical University in Beijing.
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The Mini-Mental Status Examination was used to define cognitive impairment (score: 0–17)
[19]. Activity of daily living (ADL) was assessed based on self-reported performance of the
following six self-care tasks: dressing, eating, toileting, bathing, indoor activities, and
continence. ADL was defined as normal if an individual could deal with all six tasks
independently; otherwise ADL was defined as restricted [20].
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Hypertension was defined as systolic blood pressure≥140mmHg and/or diastolic blood
pressure≥90mmHg, and/or being on antihypertensive therapy. Central obesity was defined
as waist circumference ≥85cm in men or waist circumference ≥80cm in women participants.
Type 2 diabetes mellitus was defined as fasting plasma glucose≥7.0 mmol/L or self-report of
current diabetes related medication use. Anemia was defined as hemoglobin <130g/L in men
or hemoglobin <120g/L in women. Abnormally high LDL-C level was defined as ≥3.37
mmol/L, and low HDL-C was defined as <1.04 mmol/L (15). Different LDL-C levels cut
points were used to define higher LDL-C level, including LDL-C≥3.12 mmol/L and LDLC≥2.85 mmol/L. Chronic kidney disease (CKD) was assessed from estimated glomerular
filtration rate (eGFR) less than 60 ml/min per 1.73 m2 and/or albuminuria [21]; The eGFR
was calculated with the modification of diet in renal disease (MDRD) equations for Chinese:
eGFR=175 (serum creatinine)−1.234 ×age−0.179×0.79(if female) [22].
Statistical Analysis
The characteristics of participants were compared using t-test for continuous variables and
Chi-square tests for categorical variables between death versus survival, and survival versus
lost-to-follow-up, respectively. Mortality rate for 100-person-years was calculated by the
life table method, which was partly adjusted for the influence of lost-to-follow-up.
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The survival time was calculated from the date of the baseline survey to the date of death,
and was defined as 38 months for those censored participants who survived or were lost-tofollow-up. Survival rate was estimated with the Kaplan-Meier product-limit method, and
compared with the log-rank test. Schoenfold residual error method was used for the
proportional hazards assumption test; the correlation coefficient was 0.04 and the p value
was 0.35, which showed that it met the proportional hazards assumption. Crude and adjusted
HRs for LDL-C concentrations were estimated using Cox proportional hazards models. In
Model 1, HRs were adjusted for sex, age and marital status were adjusted. And current
smoking, current alcohol drinking, and tea drinking were further included in Model 2.
Central obesity, cognitive impairment, ADL restriction and blindness were further added in
Model 3. Anemia, hypertension, type 2 diabetes mellitus, CKD and HDL-C were
additionally added in the Model 4.
To address whether the associations between LDL-C and mortality were stable, models were
performed using different LDL-C concentrations as cut points. To explore gender
differences and the possibility that low LDL-C concentration may be a consequence of acute
disease that causes increased mortality, these analyses were also stratified by gender and by
excluding deaths in the first year of follow-up. To clarify the effect of lost-to-follow-up on
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the results, sensitivity analyses were conducted by censoring lost-to-follow-up at baseline (0
month) or follow-up assessment (38 months), or at the midpoint of follow-up (19 months).
Statistical analyses were performed with SAS, version 9.13 (SAS Institute Inc, Cary, NC,
USA). 2-sided p value <0.05 was considered significant

Results

Author Manuscript

A total of 935 participants aged 80 years or older were enrolled in the baseline survey in
2009. The mean age of the participants was 94.2 years, and 69% of them were women.
Approximately 8% (73/935) of participants were lost-to-follow-up. A total of 862
participants were successfully followed-up, and 447 died. Characteristics of those who
survived, died or were lost-to-follow-up were compared (Table 1). The mean baseline age of
those who died was significantly higher than those who survived. The mean baseline values
of hemoglobin, systolic blood pressure, diastolic blood pressure and LDL-C were lower
among those who died compared to those who survived. Participants who survived had a
higher prevalence of central obesity, lower prevalence of cognitive impairment, ADL
restrictions, blindness, and CKD than those who died. No significant difference was found
for all covariates between those who survived and those who were lost-to-follow-up.
The all-cause mortality rate in 3 years was 21.4 per 100 person-years for all subjects, 19.6
for males and 22.3 for females; and it was 12.1 per 100 person-years for octogenarians, 20.9
for nonagenarians and 33.1 for centenarians (Figure 1).
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The average LDL-C level was 2.06 mmol/L for all participants, 1.87 and 2.14 mmol/L for
men and women, respectively. The prevalence of abnormally high LDL-C (≥3.37 mmol/L)
was 5.7% for all participants, and 3.4% for men and 6.6% for women. The average LDL-C
level was lower among participants who died (2.00 mmol/L) than those who survived (2.10
mmol/L) (p=0.04).
When LDL-C was analyzed as a continuous variable, each 1 mmol/L increase in LDL-C
corresponded to an 18% relative decrease in mortality risk for all participants with HR [95%
CI] 0.81 [0.71–0.92] for all participants ( 0.71 [0.53–0.96] for men, and 0.80 [0.69–0.93] for
women).
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The crude mortality risk ratio for an abnormally high LDL-C concentration (≥3.37 mmol/L)
was 0.65 (0.41–1.03). When demographic variables were adjusted (Model 1), those who had
an abnormally higher LDL-C level had a 40% lower risk of mortality than those had a lower
level of LDL-C (HR, 0.60; 95% CI, 0.38–0.96). The inverse association remained
statistically significant after further adjusting for other variables (Table 2). Figure 2 shows
the survival curves for the oldest old with lower and abnormally higher baseline LDL-C
levels.
We further examined the mortality risk for different cutoff values of LDL-C concentrations
(Table 3). At all cutoff values, participants with higher LDL-C levels had a significantly
lower risk of mortality compared to those with lower LDL-C levels. After excluding those
who died during the first year of follow-up, censoring at 19 months, or deleting all lost-to-
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follow-up, the significant associations were marginally significant but the significant
association of higher concentrations of LDL-C with mortality risk remained. The results for
each 1 mmol/L increase of LDL-C concentration with mortality risk also remained
significant or marginally significant (Table 3 and 4).

Discussion

Author Manuscript

Our results indicated that a higher level of LDL-C was inversely associated with 3-year allcause mortality among the Chinese oldest old. Compared with participants who had a lower
LDL-C, those with high concentrations had a 40% lower mortality risk, which was
consistent with several other studies [9–14, 21]. A follow-up study in France reported that
lower level of LDL-C was associated with increased mortality risk for hospitalized elderly
patients [11]. Studies further demonstrated that higher LDL-C was associated with reduced
risk of mortality for both Japanese very elderly [13] and oldest old [23]. This phenomenon
was also found in an elderly Brazilian cohort [9], elderly Italian women [14], non-demented
elderly [11] and elderly patients with heart failure [12] in the United States.
There are several possible explanations for the inverse association between LDL-C level and
mortality risk, First, evidence from animal experiments and epidemiological studies
suggested that higher LDL-C affects the immune system, which may improve survival
through enhanced defense against bacteria and viruses, or by raising delivery of lipids to
cells which may promote the immune response as well as tissue repair [24]. Furthermore, a
cohort study demonstrated that high LDL-C may improve the odds of survival in the context
of fever and sepsis [6].

Author Manuscript

Second, epidemiological studies suggest that low LDL-C in the oldest old may exert an
indirect effect to increase non-cardiovascular mortality [4]. It was not possible to establish a
direct link of low LDL-C to an adverse effect on vascular mortality or non-vascular
mortality because of the unavailable cause-specific mortality in our study. Some studies
found low LDL-C was an independent predictor of depression [25], cancer [5], injury,
homicides and suicide [26]. In other studies, LDL-C was reported to have an inverse
association with death from liver diseases [7], intra parenchymal haemorrhage [27], and
advanced chronic kidney disease [28].
Third, LDL-C was highly correlated to total cholesterol and among the oldest old, low total
cholesterol was associated with increased mortality in the oldest old [29]. This phenomenon
was also found by other studies of elderly [30] and middle aged [31] people.

Author Manuscript

Fourth, perhaps individuals susceptible to the vascular effects of high LDL-C had already
died before aged 80 years, and thus were not included in the sample. The individuals who
remained would be a select group with lower cholesterol whose genetic makeup or other
factors protect them from the effects of high LDL-C level and thereby enhance survival. To
a certain extent our data supported this hypothesis, the concentrations of LDL-C in the
oldest old was very low in our study.
Several studies show that higher LDL-C increased all-cause mortality and lower LDL-C is
beneficial in the elderly [3, 4]. A possible explanation for the different results in the present
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study is that, unlike the studies noted, we focus on the oldest old and have sufficient
numbers aged 80 years and older to make meaningful conclusions. It is likely that successful
aging of the oldest old may depend on a complex restructuring of physiological mechanism
and adaptation of metabolism, it is likely that their metabolism is able to adapt to the
challenges of aging, detrimental factors during early and middle ages may become
protective in later life.
Moreover, it is also notable that a relatively lower LDL-C in the oldest old is extensively
advertised in some communities even though this age-group is not well represented in
epidemiological or clinical trials. But according to our study, and those of others, keeping
higher LDL-C rather than lower concentration is beneficial to their survival for those aged
80 years or older. More epidemiological and clinical data are needed for primary prevention
of mortality in the oldest old.
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Strengths and Limitations
This is the first study using a relatively large sample of oldest old to investigate the
associations of LDL-C and all-cause mortality. It is a longitudinal prospective study, which
has a greater power to assess the epidemiological association between LDL-C and mortality.
This study has several limitations. We did not investigate treatment with lipid-lowering
drugs, but it likely had little effect on our results because only a few participants reported
being diagnosed by a doctor as having dyslipidemia. Exploration of potential intermediate
variables, such as the diseases causing death, was not performed because of the unavailable
cause-specific mortality data. In addition, our study was focused on Chinese oldest old, so
our results may not be applicable to other ethnic or age groups.
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Conclusions
In conclusion, our cohort study provides epidemiological evidence that higher levels of
LDL-C were associated with better survival among the oldest old. We suggest that more
interventional studies are needed to elucidate the clinical effects of higher LDL-C level in
the oldest old.
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Figure 1.

3-year all-cause mortality rate (person-year) among Chinese oldest old by gender

Author Manuscript
Author Manuscript
Atherosclerosis. Author manuscript; available in PMC 2015 May 22.

LV et al.

Page 11

Author Manuscript
Author Manuscript

Figure 2.

Survival curves for Chinese oldest old stratified by baseline LDL-C level
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38(8.5)
235(52.6)
1.23±0.32
119(26.6)
2.00±0.74
19(4.3)

Alcohol drinking habits

Tea drinking habits

Central obesity

Cognitive impairment

ADL restriction

Blindness

Hemoglobin (g/L) ╪

Anemia

Systolic blood pressure (mmHg) ╪

Diastolic blood pressure (mmHg) ╪

Hypertension

Fasting plasma glucose (mmol/L) ╪

Diabetes

CKD(chronic kidney disease)

HDL-C (mmol/L) ╪

Abnormal HDL-C

LDL-C level§

Abnormally higher LDL-C

398(89.0)

Not in marriage

Current smoking practice

49(11.0)

In marriage

Marital status

Age,

96.8±7.3

318(71.1)

Female

year§

129(28.9)

Male

Sex

Died, N=447 (%)

Characteristic
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28(6.8)

2.10±0.79

123(29.6)

1.20±0.32

160(38.6)

40(9.6)

5.34±1.61

260(62.7)

79.3±14.7

143.3±25.7

178(42.9)

126.2±22.4

40(9.6)

56(13.5)

147(35.4)

162(39.0)

100(24.1)

69(16.0)

65(15.7)

316(76.1)

99(23.9)

91.7±7.6

278(79.4)

137(30.6)

415(44.4)

Survived, N=415 (%)

0.10

0.04

0.32

0.19

0.01

0.56

0.74

0.14

0.03

0.09

0.01

0.01

0.01

0.01

0.01

0.01

0.25

0.77

0.71

0.01

0.01

0.19

P-value*

6(8.2)

2.15±0.88

16(21.9)

1.22±0.29

28(38.4)

11(15.1)

5.55±1.35

38(52.1)

79.4±14.7

139.6±26.1

37(50.7)

125.3±19.5

5(6.9)

23(31.5)

31(18.5)

26(35.6)

16(21.9)

7(9.6)

15(20.1)

57(78.1)

16(21.9)

94.4±7.9

49(67.1)

24(32.9)

73(7.8)

Lost to follow-up, N=73 (%)

Characteristics of 935 Chinese oldest old by the outcome over 3 years of follow-up

0.65

0.67

0.18

0.61

0.01

0.16

0.30

0.09

0.95

0.27

0.22

0.74

0.45

0.20

0.52

0.58

0.69

0.13

0.30

0.72

0.98

0.98

P-value†
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Data reported as means±SD for continuous variables.

The lost-to-follow-up was compared with the “survived” group.

╪

†

The dead compared with the “survived” group.

*

Abbreviations: ADL=activities of daily living; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; CKD= chronic kidney disease; Abnormal HDL-C level was
defined as <1.04 mmol/L; Abnormally higher LDL-C level was defined as ≥3.37 mmol/L.
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0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=no 1=yes
0=normal 1=abnormal

Tea drinking

Central obesity

Cognitive Impairment

ADL restriction

Blindness

Anemia

Hypertension

Diabetes

CKD

Abnormal HDL-C

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.65(0.41–1.03)

Crude

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.91(0.72–1.15)

1.02(0.78–1.33)

1.04(0.78–1.38)

1.62(1.17–2.25)

1.69(1.49–1.91) â

1.69(1.49–1.91) â
1.62(1.17–2.25)

1.32(1.03–1.67)*

1.32(1.05–1.65)*

â

0.60(0.38–0.96)*

0.60(0.38–0.96)*

â

Model 2
OR(95%CI)

Model 1
OR(95%CI)

-

-

-

-

1.09(0.88–1.36)

1.55(1.28–1.89)**

0.87(0.62–1.22)

0.94(0.78–1.14)

1.13(0.93–1.34)

1.42(1.09–1.83)**

1.38(1.06–1.78)*
-

1.57(1.26–1.97) **

1.56(1.25–1.95) **

0.64(0.52–0.79) **

0.85(0.67–1.09)

1.58(1.27–1.96) **

â

1.08(0.83–1.40)

1.09(0.81–1.46)

1.49(1.07–2.08)*

1.38(1.20–1.60) â

1.40(1.09–1.79) â

0.60(0.37–0.95)*

Final model
OR(95%CI)

1.50(1.21–1.86) **

0.65(0.53–0.80)

0.93(0.73–1.17)

1.05(0.81–1.37)

1.07(0.80–1.43)

1.50(1.08–2.08)*

1.42(1.24–1.63) â

1.36(1.06–1.74)*

0.64(0.40–1.00)*

Model 3
OR(95%CI)
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P<0.01.

P<0.05

**

*

Abbreviations: ADL=activities of daily living; CKD=chronic kidney disease; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; Abnormal HDL-C level was defined
as <1.04 mmol/L; Abnormally high LDL-C level was defined as ≥3.37 mmol/L.

0=no 1=yes

Current alcohol drinking

0=80–89 1=90–99 2=100-

Age

Current smoking

0=female 1=male

Sex

0=in marriage 1= not in marriage

0=low 1=abnormally higher

Abnormally higher LDL-C

Marital status

Values

Variables

Cox’s proportional-hazards models for predicting 3-year all-cause mortality among 935 Chinese oldest old.
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0.80(0.69–0.93) **
0.80(0.69–0.93) **
0.81(0.69–0.94) **

0.71(0.53–0.96)*
0.73(0.54–0.98)*
0.74(0.56–0.99)*

Censoring at 38 months
Censoring at 19 months
Deleting all lost-to-follow-up
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P<0.01.

Adjusted for sex, age, marital status, current smoking, current alcohol drinking, tea drinking, central obesity, cognitive impairment, ADL restriction, blindness, chronic kidney disease, anemia,
hypertension, type 2 diabetes mellitus and abnormal HDL-C level.

†

**

P<0.05,

*

0.82(0.72–0.94)*

0.82(0.71–0.93) **

0.81(0.71–0.92) **

0.72(0.54–0.94)*

0.68(0.50–0.92)*

0.71(0.54–0.94)*

0.67(0.50–0.92)*

0.71(0.37–1.38)

0.72(0.55–0.95)*

0.69(0.51–0.94)*

Deleting all lost-to-follow-up

0.59(0.41–0.86) **

0.58(0.39–0.87) **

0.69(0.36–1.34)

0.59(0.41–0.85) **

0.57(0.38–0.85) **

Censoring at 19 months

0.59(0.41–0.85) **

0.57(0.38–0.85) **

0.67(0.35–1.29)

0.41(0.15–1.16)

Deleting all lost-to-follow-up

0.64(0.40–1.03)

0.66(0.40–1.11)

0.62(0.39–0.99)*

0.60(0.37–0.958)*

0.59(0.35–0.98)*
0.63(0.38–1.0)

Total

Women

Censoring at 38 months

0.41(0.15–1.17)

Censoring at 19 months

Abbreviations: LDL-C=low-density lipoprotein cholesterol;

Each 1 mmol/L increase in LDL-C

LDL-C≥2.85mmol/L (110mg/dL)

0.43(0.15–1.21)

0.40(0.12–1.32)

Deleting all lost-to-follow-up
Censoring at 38 months

0.40(0.12–1.31)

Censoring at 19 months

LDL-C≥3.12mmol/L (120mg/dL )

0.41(0.12–1.34)

Censoring at 38 months

LDL-C≥3.37mmol/L (130mg/dL)

Men

Censoring time

Cut-off

HR(95%CI) (adjusted with final model) †

Sensitivity analysis of the association between LDL-C level and mortality by censoring time for loss-to-follow-up.
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0.48(0.15–1.58)
0.71(0.33–1.51)
0.73(0.51–1.03))

LDL-C≥3.12mmol/L (120mg/dL )

LDL-C≥2.85mmol/L (110mg/dL)

Each 1mmol/L increase in LDL-C

0.59(0.34–1.02)
0.64(0.43–0.97)*
0.69(0.50–0.95)*
0.83(0.71–0.96)*

0.61(0.39–0.95)*
0.63(0.44–0.91)*
0.82(0.69–0.98)*

Adjusted for sex, age, marital status, current smoking, current alcohol drinking, tea drinking, central obesity, cognitive impairment, ADL restriction, blindness, chronic kidney disease, anemia,
hypertension, type 2 diabetes mellitus and abnormal HDL-C level

†

P<0.05.

*

Total

0.59(0.32–1.07)

Women

Abbreviations: LDL-C=low-density lipoprotein cholesterol.

0.41(0.10–1.77)

Men

HR(95%CI) (adjusted with final model) †

LDL-C≥3.37mmol/L(130mg/dL)

Cut-off

The mortality risk for higher LDL-C after the exclusion of mortality in the first year.
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